Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra L Kweder

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Birth Defects Research. Part A, Clinical and Molecular Teratology|August 16, 2008
Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st centurySandra L Kweder
Clinical Pharmacology and Therapeutics|August 27, 2019
Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?Tania Teixeira, Sandra L Kweder, Agnes Saint-Raymond
American Family Physician|June 27, 2003
Information on medication use in pregnancyKathleen Uhl, Dianne L Kennedy, Sandra L Kweder
American Family Physician|March 5, 2003
Accurate information on drug effects on pregnancy is crucialKathleen Uhl, Dianne L Kennedy, Sandra L Kweder
Drug Safety|September 21, 2002
Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugsKathleen Uhl, Dianne L Kennedy, Sandra L Kweder
Drug Safety|March 9, 2004
Pregnancy exposure registriesDianne L Kennedy, Kathleen Uhl, Sandra L Kweder
Drug Safety|December 30, 2006
Can we ensure the safe use of known human teratogens?: The iPLEDGE test caseMargaret A Honein, Jill A Lindstrom, Sandra L Kweder
Clinical Pharmacology and Therapeutics|July 16, 2019
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and WhyMwango Kashoki, Zahra Hanaizi, Stella Yordanova, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Regional Approaches to Expedited Drug Development and Review: Can Regulatory Harmonization Improve Outcomes?Elizabeth Richardson, Gregory Daniel, David R Joy, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Birth Defects Research. Part A, Clinical and Molecular Teratology|August 16, 2008
Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st centurySandra L Kweder
Clinical Pharmacology and Therapeutics|August 27, 2019
Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?Tania Teixeira, Sandra L Kweder, Agnes Saint-Raymond
American Family Physician|June 27, 2003
Information on medication use in pregnancyKathleen Uhl, Dianne L Kennedy, Sandra L Kweder
American Family Physician|March 5, 2003
Accurate information on drug effects on pregnancy is crucialKathleen Uhl, Dianne L Kennedy, Sandra L Kweder
Drug Safety|September 21, 2002
Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugsKathleen Uhl, Dianne L Kennedy, Sandra L Kweder
Drug Safety|March 9, 2004
Pregnancy exposure registriesDianne L Kennedy, Kathleen Uhl, Sandra L Kweder
Drug Safety|December 30, 2006
Can we ensure the safe use of known human teratogens?: The iPLEDGE test caseMargaret A Honein, Jill A Lindstrom, Sandra L Kweder
Clinical Pharmacology and Therapeutics|July 16, 2019
A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and WhyMwango Kashoki, Zahra Hanaizi, Stella Yordanova, et al.
Therapeutic Innovation & Regulatory Science|May 2, 2018
Regional Approaches to Expedited Drug Development and Review: Can Regulatory Harmonization Improve Outcomes?Elizabeth Richardson, Gregory Daniel, David R Joy, et al.
Pageof 1